Literature DB >> 16608502

Hydrops lysosomalis generalisatus--an underestimated side effect of hydroxyethyl starch therapy?

Martin Schmidt-Hieber1, Christoph Loddenkemper, Stefan Schwartz, Gesine Arntz, Eckhard Thiel, Michael Notter.   

Abstract

Hydroxyethyl starch (HES) is usually considered to be associated with limited side effects. Generalized foamy cell macrophage syndrome after HES therapy has rarely been reported since Schaefer first described it as 'hydrops lysosomalis generalisatus' in 1982. We present a 19-yr-old male who received large amounts of HES. A bone marrow and a liver biopsy were performed because of persistent thrombocytopenia and liver dysfunction. We found severe infiltration of foamy cell degenerated macrophages in both organ systems, indicating that sequelae of HES therapy have to be included in the differential diagnosis of bone marrow and liver dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16608502     DOI: 10.1111/j.1600-0609.2006.00657.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  12 in total

1.  Practice of volume therapy in patients with severe sepsis: results from a nationwide sepsis prevalence study.

Authors:  Christiane S Hartog; Frank M Brunkhorst; Frank Bloos; Holger Bogatsch; Christoph Engel; Kerstin Sengebusch; Konrad Reinhart; Maximilian Ragaller
Journal:  Intensive Care Med       Date:  2009-12-02       Impact factor: 17.440

Review 2.  Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis.

Authors:  Amit Patel; Umeer Waheed; Stephen J Brett
Journal:  Intensive Care Med       Date:  2013-02-22       Impact factor: 17.440

Review 3.  Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.

Authors:  Romuald Bellmann; Clemens Feistritzer; Christian J Wiedermann
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

Review 4.  [Limited applications for hydroxyethyl starch : background and alternative concepts].

Authors:  M Rehm
Journal:  Anaesthesist       Date:  2013-08       Impact factor: 1.041

5.  Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients.

Authors:  Konrad Reinhart; Anders Perner; Charles L Sprung; Roman Jaeschke; Frederique Schortgen; A B Johan Groeneveld; Richard Beale; Christiane S Hartog
Journal:  Intensive Care Med       Date:  2012-02-10       Impact factor: 17.440

6.  [Study protocol of the VISEP study. Response of the SepNet study group].

Authors:  K Reinhart; F M Brunkhorst; C Engel; F Bloos; A Meier-Hellmann; M Ragaller; N Weiler; O Moerer; M Gruendling; M Oppert; S Grond; D Olthoff; U Jaschinski; S John; R Rossaint; T Welte; M Schaefer; P Kern; E Kuhnt; M Kiehntopf; T Deufel; C Hartog; H Gerlach; F Stüber; H-D Volk; M Quintel; M Loeffler
Journal:  Anaesthesist       Date:  2008-07       Impact factor: 1.041

Review 7.  CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.

Authors:  Christiane Hartog; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

Review 8.  Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis.

Authors:  Nicolai Haase; Anders Perner; Louise Inkeri Hennings; Martin Siegemund; Bo Lauridsen; Mik Wetterslev; Jørn Wetterslev
Journal:  BMJ       Date:  2013-02-15

Review 9.  Relative survival benefit and morbidity with fluids in severe sepsis - a network meta-analysis of alternative therapies.

Authors:  M Bansal; A Farrugia; S Balboni; G Martin
Journal:  Curr Drug Saf       Date:  2013-09

10.  Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial.

Authors:  Piotr Wittbrodt; Nicolai Haase; Dominika Butowska; Robert Winding; Jesper B Poulsen; Anders Perner
Journal:  Crit Care       Date:  2013-02-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.